Placeholder

Biomarkers Across Drug Development

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1977. Categories: , .

Product Description

Biomarkers have a multitude of applications, such as detecting disease early on, identifying potential drug targets, predicting patient response to medication, and accelerating clinical trials. The promise of biomarkers to shorten drug development time and decrease costs in the long term is likely to act in tandem to spur growth in the biomarker analysis market, which has excellent potential, according to a recent report by Frost & Sullivan.
“Biomarkers are central to an effective personalized healthcare strategy as they play an important role in determining not only the magnitude of the benefit patients will derive from a treatment, but also which patients will benefit,” says Hal Barron, global head, product development…

Experts on this topic
Hal Barron, Global Head, Product Development and Chief Medical Officer, at Roche
Nagaraja Srivatsan, VP and Head of Life Sciences, North America, at Cognizant
Kerri Schoedel, Ph.D., Scientific Director, Clinical Pharmacology, at Kendle
Peter Smith, Ph.D., Senior VP, Nonclinical Development Sciences, at Millennium Pharmaceuticals Inc.: The Takeda Oncology Company
Brian Sanderson, M.D., Medical Director, Chiltern Early Phase
Alain Stricker-Krongrad, Ph.D., Chief Scientific Officer at Charles River
Thomas Jones, Ph.D., Senior Director, Toxicology and Pathology, at Eli Lilly and Company
Jerome Bailey, VP, Early Phase Business Center, at Omnicare Clinical Research
Jamie Dananberg, M.D., Executive Director of Clinical Pharmacology at Eli Lilly and Company
Murray Ducharme, Pharm.D., Chief Science Officer for Cetero Research

FEEDBACK